Education
About Us
Working with TipRanks
Follow Us
Esperion (CH:0ET)
:0ET
0ET Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Esperion News
PremiumCompany Announcements
Esperion Gains Strong Shareholder Support at Annual Meeting
PremiumCompany Announcements
Esperion Therapeutics Reports Mixed Q1 2025 Results
PremiumCompany Announcements
Esperion Therapeutics Reports Strong Q1 2025 EarningsBulls Say, Bears Say
Bulls Say
Pipeline ExpansionEsperion is expanding its early-stage development pipeline with a new program targeting primary sclerosing cholangitis (PSC).
Revenue GrowthRevenue continues to grow, with a 41% increase in NEXLETOL/NEXLIZET U.S. product revenue driven by retail prescription growth.
Strategic PartnershipsEsperion announced a license and distribution agreement with HLS Therapeutics for the commercialization of NEXLETOL and NEXLIZET in Canada.
Bears Say
BA Franchise ConcernsThe pivot to liver diseases is likely raising concerns over Esperion's BA franchise.
Development RisksThe selection of PSC as an initial indication is seen as high risk due to developmental challenges and historical difficulties.
Financial ConcernsEsperion's current cash position is raising concerns about its ability to meet additional priorities and achieve sustained profitability.
Options Prices
Currently, No data available
---
Ownership Overview
1.57% Insiders
14.13%
Mutual Funds
20.05% Other Institutional Investors
54.26% Public Companies and Individual Investors
0ET FAQ
What was Esperion’s price range in the past 12 months?
Currently, no data Available
What is Esperion’s market cap?
Currently, no data Available
When is Esperion’s upcoming earnings report date?
Esperion’s upcoming earnings report date is Aug 05, 2025 which is in 63 days.
How were Esperion’s earnings last quarter?
Esperion released its earnings results on May 06, 2025. The company reported -CHF0.175 earnings per share for the quarter, missing the consensus estimate of -CHF0.129 by -CHF0.046.
Is Esperion overvalued?
According to Wall Street analysts Esperion’s price is currently Undervalued.
Does Esperion pay dividends?
Esperion does not currently pay dividends.
What is Esperion’s EPS estimate?
Esperion’s EPS estimate is -0.12.
How many shares outstanding does Esperion have?
Currently, no data Available
What happened to Esperion’s price movement after its last earnings report?
Esperion reported an EPS of -CHF0.175 in its last earnings report, missing expectations of -CHF0.129. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Esperion?
Currently, no hedge funds are holding shares in CH:0ET
Esperion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.16 (― Downside)
$5.16 (― Downside)
Blogger Sentiment
Bullish
CH:0ET Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $28.5K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.50%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.14%
Trailing 12-Months
Company Description
Esperion
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
0ET Company Deck
0ET Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a strong overall performance with significant revenue growth, expanded market access, and key pipeline advancements. However, challenges such as seasonal sales impacts and confusion due to policy changes were acknowledged. The highlights, particularly the revenue growth and guideline inclusion, outweigh the lowlights.Read More>0ET Stock 12 Month Forecast
Average Price Target
CHF5.16
Emergent Biosolutions
―
Ironwood Pharma
―
Lifecore Biomedical
―
Aquestive Therapeutics
―
Journey Medical Corp
―